Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Multicentre, 48 Week Trial of Maraviroc With or Without Metformin for Hepatic Steatosis in HIV-1-infected Adults on Combination Antiretroviral Therapy

Next Previous
X
Search
Trial Profile

A Randomised, Multicentre, 48 Week Trial of Maraviroc With or Without Metformin for Hepatic Steatosis in HIV-1-infected Adults on Combination Antiretroviral Therapy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Maraviroc (Primary) ; Metformin (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacodynamics
  • Acronyms MAVMET

    • Most Recent Events

    • 03 Nov 2021 Status changed from active, no longer recruiting to completed.
    • 30 Oct 2021 Primary endpoint has not been met. (Change in percentage of liver fat as measured by 1H MRS over 48 weeks)as per results presented at the 18th European AIDS Conference
    • 30 Oct 2021 Results presented at the 18th European AIDS Conference

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top